MX2017011606A - Metodos para preparar buprenorfina. - Google Patents

Metodos para preparar buprenorfina.

Info

Publication number
MX2017011606A
MX2017011606A MX2017011606A MX2017011606A MX2017011606A MX 2017011606 A MX2017011606 A MX 2017011606A MX 2017011606 A MX2017011606 A MX 2017011606A MX 2017011606 A MX2017011606 A MX 2017011606A MX 2017011606 A MX2017011606 A MX 2017011606A
Authority
MX
Mexico
Prior art keywords
buprenorphine
preparing
methods
acetate salt
acetate salts
Prior art date
Application number
MX2017011606A
Other languages
English (en)
Inventor
Frederick M Huntley C
Wayne Kataisto Erik
Alfred REISCH Helge
Sharma Archana
Larry STYMIEST Jake
Original Assignee
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Tech filed Critical Rhodes Tech
Publication of MX2017011606A publication Critical patent/MX2017011606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente descripción hace referencia a sales de acetato de buprenorfina y sus anhidros, solvatos, hidratos y formas cristalinas y en la que las sales de acetato de buprenorfina se encuentran esencialmente libres de impurezas. De manera adicional, la descripción provee un método para preparar las sales de acetato, la base libre de buprenorfina preparada a partir de las sales de acetato, otras sales preparadas a partir de la base libre y las composiciones farmacéuticas de estas esencialmente libre de impurezas.
MX2017011606A 2015-03-10 2016-03-09 Metodos para preparar buprenorfina. MX2017011606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
PCT/IB2016/051332 WO2016142877A1 (en) 2015-03-10 2016-03-09 Acetate salt of buprenorphine and methods for preparing buprenorphine

Publications (1)

Publication Number Publication Date
MX2017011606A true MX2017011606A (es) 2017-10-26

Family

ID=55524412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011606A MX2017011606A (es) 2015-03-10 2016-03-09 Metodos para preparar buprenorfina.

Country Status (19)

Country Link
US (6) US10406152B2 (es)
EP (1) EP3283490A1 (es)
JP (2) JP6660399B2 (es)
KR (2) KR20200045010A (es)
CN (1) CN107660207B (es)
AR (1) AR103902A1 (es)
AU (2) AU2016230750B2 (es)
BR (1) BR112017019357A2 (es)
CA (2) CA2977732C (es)
CO (1) CO2017009130A2 (es)
EA (1) EA201792014A1 (es)
IL (1) IL254384A0 (es)
MA (1) MA45902A (es)
MX (1) MX2017011606A (es)
NZ (1) NZ735736A (es)
PH (1) PH12017501641A1 (es)
SG (1) SG11201707350TA (es)
TW (2) TW202037597A (es)
WO (1) WO2016142877A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105247038B (zh) 2013-03-15 2021-08-27 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)的微生物及其制备和使用方法
CN112410379B (zh) 2013-11-04 2024-12-31 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物以及制备和使用所述前体的方法
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
EP3292203A4 (en) 2015-05-04 2019-10-09 The Board of Trustees of the Leland Stanford Junior University BENZYL ISOCHINOLIN ALKALOID (BIA) Precursor Producing Microbicides and Method for the Preparation and Use Thereof
WO2016183023A1 (en) 2015-05-08 2016-11-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of producing epimerases and benzylisoquinoline alkaloids
BR112019007884A2 (pt) 2016-10-18 2019-07-02 Antheia Inc métodos para a produção de alcaloides nor-opioides e nal-opioides de benzilisoquinolina
GB2579940B (en) 2017-08-03 2022-11-30 Antheia Inc Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
BR112020016576A2 (pt) * 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
CN113784758B (zh) 2019-03-08 2025-03-07 小利兰·斯坦福大学托管委员会 产生莨菪烷生物碱(ta)的非植物宿主细胞及其制备和使用方法
IL317873A (en) * 2022-06-24 2025-02-01 Alar Pharmaceuticals Inc Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (es) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
JP2010511726A (ja) 2006-12-04 2010-04-15 ノランコ・インコーポレーテツド １４−ヒドロキシコデイノンの濃度が低いオキシコドンの製造方法
AU2007333307B2 (en) 2006-12-11 2013-05-23 Alcon Inc. Substantially pure fluorescein
EP2311498A4 (en) * 2008-08-05 2013-07-24 Medrx Co Ltd EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF
WO2011005452A1 (en) 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the enrichment of buprenorphine using chromatographic techniques
AU2011307608B8 (en) * 2010-09-30 2015-08-27 Grünenthal GmbH Crystalline naloxol-PEG conjugate
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US9834562B2 (en) * 2012-12-31 2017-12-05 Rhodes Technologies 7 beta-substituted 6a, 14a-ethenomorphinans and 7beta-substituted 6a, 14a-ethanomorphinans
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
CN107660207B (zh) * 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法

Also Published As

Publication number Publication date
CO2017009130A2 (es) 2017-11-21
BR112017019357A2 (pt) 2018-06-05
TW201639856A (zh) 2016-11-16
JP2020033359A (ja) 2020-03-05
PH12017501641A1 (en) 2018-02-12
US10874662B2 (en) 2020-12-29
CA2977732A1 (en) 2016-09-15
US20170197975A1 (en) 2017-07-13
US20190314364A1 (en) 2019-10-17
TW202037597A (zh) 2020-10-16
CN107660207A (zh) 2018-02-02
US20180235955A1 (en) 2018-08-23
AU2019203308A1 (en) 2019-05-30
EP3283490A1 (en) 2018-02-21
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
JP2018507882A (ja) 2018-03-22
WO2016142877A1 (en) 2016-09-15
AU2016230750A1 (en) 2017-10-12
NZ735736A (en) 2019-02-22
EA201792014A1 (ru) 2018-01-31
CN107660207B (zh) 2020-09-29
CA3104099A1 (en) 2016-09-15
US10406152B2 (en) 2019-09-10
KR20200045010A (ko) 2020-04-29
US20180162866A1 (en) 2018-06-14
KR20170137738A (ko) 2017-12-13
US20210046066A1 (en) 2021-02-18
JP6660399B2 (ja) 2020-03-11
MA45902A (fr) 2019-06-19
US20190298713A1 (en) 2019-10-03
US10278967B2 (en) 2019-05-07
AU2016230750B2 (en) 2019-05-30
CA2977732C (en) 2021-02-23
TWI699367B (zh) 2020-07-21
AR103902A1 (es) 2017-06-14
US9926329B2 (en) 2018-03-27
IL254384A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
PH12017501641A1 (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
SA520411222B1 (ar) مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق
PH12020550703A1 (en) Sulfonamide compounds and use thereof
IL271938A (en) A method for making synthesis gas
IL271939A (en) A method for making synthesis gas
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
IL271941A (en) A method for making synthesis gas
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017008136A (es) Sal de l-tartrato de pridopidina.
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
EP4606784A3 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
MX2021010078A (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
ZA201908433B (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
WO2016024286A3 (en) An improved process for synthesis of lenalidomide
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
IL290625A (en) Crystalline forms of quinoline analogs and their salts, compositions, and methods of their use
WO2019240698A3 (en) Oral pharmaceutical composition comprising posaconazole
HUE059444T2 (hu) Morfolinszármazék sója és ennek kristályformája, valamint ezek elõállítási eljárása, gyógyszerkészítménye és alkalmazása
EP3190115A4 (en) Salt of cephalosporin derivative, crystalline solid form of same and method for producing same
WO2015197860A3 (en) Thapsigargin analogues and methods of preparing them
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof